Feasibility of sequential high-dose chemotherapy in advanced pediatric solid tumors

Pediatric Hematology and Oncology

Volumn 27, Issue 1, 2010, Pages 1-12

  Kwon, Seung Yeon ^a   Won, Sung Chul ^a   Han, Jung Woo ^a   Shin, Yoon Jung ^a   Lyu, Chuhl Joo ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Chemotherapy; Childhood solid tumors; High dose

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; ANTIFUNGAL AGENT; CARBOPLATIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; ETOPOSIDE; MELPHALAN; MESNA;

ADVANCED CANCER; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; BLOOD CLOTTING DISORDER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG MEGADOSE; EWING SARCOMA; FEASIBILITY STUDY; FEMALE; FEVER; FOLLOW UP; HUMAN; INFECTION PREVENTION; MALE; MEDICAL RECORD REVIEW; MORTALITY; MULTIPLE CYCLE TREATMENT; MYCOSIS; NASOPHARYNX CANCER; NAUSEA; NAUSEA AND VOMITING; NEUROBLASTOMA; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PNEUMOCYSTIS PNEUMONIA; PRESCHOOL CHILD; RADIATION DOSE; RHABDOMYOSARCOMA; SCHOOL CHILD; SIDE EFFECT; STOMATITIS; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION; VEIN OCCLUSION; VOMITING; YOLK SAC TUMOR;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; MALE; NEOPLASMS; NEUROBLASTOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RHABDOMYOSARCOMA; SALVAGE THERAPY; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 76649127770     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/14992020903352226     Document Type: Article

References (28)

1. Chan KW, Petropoulos D, Choroszy M, et al. High-dose sequential chemotherapy and autologous stem cell reinfusion in advanced pediatric solid tumors. Bone Marrow Transplant. 1997;20:1039-1043.
2. Pritchard J, Cotterill SJ, Germond SM, Imeson J, de Kraker J, Jones DR. High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group. Pediatr Blood Cancer. 2005;44:348-357.
3. Meyers PA, Krailo MD, Ladanyi M, et al. High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. J Clin Oncol. 2001;19:2812-281220.
4. Berthold F, Boos J, Burdach S, et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol. 2005;6:649-658.
5. Kletzel M, Katzenstein HM, Haut PR, et al. Treatment of high-risk neuroblastoma with tripletandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II Study. J Clin Oncol. 2002;20:2284-2292.
6. George RE, Li S, Medeiros-Nancarrow C, et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol. 2006;24:2891-2896.
7. Brodeur GM, Seeger RC, Barrett A, et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol. 1988;6:1874-1881.
8. Won SC, Han JW, Kwon SY, et al. Autologous peripheral blood stem cell transplantation in children with non-Hodgkin's lymphoma: a report from the Korean Society of Pediatric Hematology-Oncology. Ann Hematol. 2006;85:787-794.
9. Ladenstein R, Philip T, Gardner H. Autologous stem cell transplantation for solid tumors in children. Curr Opin Pediatr. 1997;9:55-69.
10. Imaizumi M, Watanabe A, Kikuta A, et al. Improved survival of children with advanced neuroblastoma treated by intensified therapy including myeloablative chemotherapy with stem cell transplantation: a retrospective analysis from the Tohoku Neuroblastoma Study Group. Tohoku J Exp Med. 2001;195:73-83.
11. Ek ET, Choong PF. The role of high-dose therapy and autologous stem cell transplantation for pediatric bone and soft tissue sarcomas. Expert Rev Anticancer Ther. 2006;6:225-237.
12. Atra A, Pinkerton R. High-dose chemotherapy in soft tissue sarcoma in children. Crit Rev Oncol Hematol. 2002;41:191-196.
13. Verlooy J, Mosseri V, Bracard S, et al. Treatment of high risk medulloblastomas in children above the age of 3 years: a SFOP study. Eur J Cancer. 2006;42:3004-3014.
14. Suita S, Shono K, Tajiri T, et al. Malignant germ cell tumors: clinical characteristics, treatment, and outcome: a report from the study group for Pediatric Solid Malignant Tumors in the Kyushu Area, Japan. J Pediatr Surg. 2002;37:1703-1706.
15. Sung KW, Yoo KH, Cho EJ, et al. High-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk or relapsed medulloblastoma or supratentorial primitive neuroectodermal tumor. Pediatr Blood Cancer. 2007;48:408-415.
16. Avramova B, Jordanova M, Michailov G, Konstantinov D, Christosova I, Bobev D. Myeloablative chemotherapy with autologous peripheral blood stem cell transplantation in patients with poorprognosis solid tumors-Bulgarian experience. J Buon. 2006;11:433-438.
17. Marcus KJ, Shamberger R, Litman H, et al. Primary tumor control in patients with stage 3/4 unfavorable neuroblastoma treated with tandem double autologous stem cell transplants. J Pediatr Hematol Oncol. 2003;25:934-940.
18. Pradhan KR, Johnson CS, Vik TA, Sender LS, Kreissman SG. A novel intensive induction therapy for high-risk neuroblastoma utilizing sequential peripheral blood stem cell collection and infusion as hematopoietic support. Pediatr Blood Cancer. 2006;46:793-802.
19. Jakacki RI, Jamison C, Heifetz SA, Caldemeyer K, Hanna M, Sender L. Feasibility of sequential highdose chemotherapy and peripheral blood stem cell support for pediatric central nervous system malignancies. Med Pediatr Oncol. 1997;2:553-559.
20. Strother D, Ashley D, Kellie SJ, et al. Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study. J Clin Oncol. 2001;19:2696-2704.
21. Fish JD, Grupp SA. Stem cell transplantation for neuroblastoma. Bone Marrow Transplant. 2008;41:159-165.
22. Kreissman SG, Rackoff W, Lee M, Breitfeld PP. High dose cyclophosphamide with carboplatin: a tolerable regimen suitable for dose intensification in children with solid tumors. J Pediatr Hematol Oncol. 1997;19:309-312.
23. Basser RL, To LB, Begley CG, et al. Rapid hematopoietic recovery after multicycle high-dose chemotherapy: enhancement of filgrastim-induced progenitor-cell mobilization by recombinant human stem-cell factor. J Clin Oncol. 1998;16:1899-1908.
24. ShapiroCL, Ayash L,Webb IJ, et al.Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients. J Clin Oncol. 1997;15:674-683.
25. Bokemeyer C, Gillis AJ, Pompe K, et al. Clinical impact of germ cell tumor cells in apheresis products of patients receiving high-dose chemotherapy. J Clin Oncol. 2001;19:3029-3036.
26. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med. 1999;341:1165-1173.
27. Stram DO, Matthay KK, O'Leary M, et al. Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies. J Clin Oncol. 1996;14:2417-2426.
28. Kushner BH, Kramer K, LaQuaglia MP, Modak S, Yataghene K, Cheung NK. Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma. J Clin Oncol. 2004;22:4888-4892.